TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29343012

Group type: EXPERIMENTAL
Intervention: Individualized treatment regimen (2SHRZE/6HRE) with drug replacement based on DST results, treatment duration of 12 months or more if drug resistance is present, otherwise 8 months standard treatment.
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Intensified retreatment regimen (2HL(2)EZS/2HL(2)EZS(3)/4HL(2)E) with specific dosing based on body weight, total treatment duration of 8 months.
Number of subjects: 254

Group type: COMPARATOR
Intervention: Standard treatment regimen (2HREZS/6HRE) recommended by national tuberculosis program, total treatment duration of 8 months.
Number of subjects: 254
Study: 26782705

Group type: EXPERIMENTAL
Intervention: E4 (acid unstable, droplet size 0.38 mm)
Number of subjects: 12

Group type: COMPARATOR
Intervention: E1 (acid stable, droplet size 0.33 mm)
Number of subjects: 12
Study: 24612588

Group type: EXPERIMENTAL
Intervention: Parent-briefing intervention
Number of subjects: 31
Study: 21127899

Group type: EXPERIMENTAL
Intervention: Pose cycling setup
Number of subjects: 18

Group type: COMPARATOR
Intervention: Coaching intervention (4 × 1 h)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Changed bicycle setup and pedaling technique
Number of subjects: 18
Study: 19167659

Group type: EXPERIMENTAL
Intervention: Intervention Group 1 (nurses only)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Intervention Group 2 (nurses and parents)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 360
Study: 16616557

Group type: EXPERIMENTAL
Intervention: 1000 mg vitamin C and 400 IU vitamin E daily from the second trimester until delivery
Number of subjects: 2410

Group type: COMPARATOR
Intervention: Matched placebo daily from the second trimester until delivery
Number of subjects: 2410
Study: 14977764

Group type: EXPERIMENTAL
Intervention: 0.05% mequitazine eye drops
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.05% levocabastine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11783744

Group type: EXPERIMENTAL
Intervention: l‐alpha‐acetylmethadol (LAAM)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: buprenorphine
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: naltrexone
Number of subjects: 69

Group type: COMPARATOR
Intervention: non-opioid-treated controls
Number of subjects: 69
Study: 9480618

Group type: EXPERIMENTAL
Intervention: Chromium picolinate (200 micrograms/d)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Chromium yeast (200 micrograms/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8293297

Group type: EXPERIMENTAL
Intervention: Oral inositol treatment
Number of subjects: 8
Study: 3318427

Group type: EXPERIMENTAL
Intervention: Nabumetone 1,000 mg per day at bedtime
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 408522

Group type: EXPERIMENTAL
Intervention: Erythromycin estolate
Number of subjects: 152

Group type: COMPARATOR
Intervention: Erythromycin base
Number of subjects: 152
Study: 31680394

Group type: EXPERIMENTAL
Intervention: alemtuzumab/belatacept
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: rATG/belatacept
Number of subjects: 316

Group type: COMPARATOR
Intervention: rATG/tacrolimus
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: belatacept
Number of subjects: 316
Study: 30525226

Group type: EXPERIMENTAL
Intervention: 300 U of abobotulinumtoxinA (ABO)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 500 U of abobotulinumtoxinA (ABO)
Number of subjects: 21
Study: 27809345

Group type: EXPERIMENTAL
Intervention: Nebilet HCT™ (nebivolol 5 mg + hydrochlorothiazide 12.5 mg tablet)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nebilet™ (nebivolol 5 mg tablet)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clorana™ (hydrochlorothiazide 25 mg tablet)
Number of subjects: 0
Study: 26229445

Group type: EXPERIMENTAL
Intervention: Paracetamol (APAP)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 23258770

Group type: EXPERIMENTAL
Intervention: Sorafenib treatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Non-anti-angiogenic therapy (TACE)
Number of subjects: 19
Study: 21173651

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency endometrial ablation
Number of subjects: 81

Group type: COMPARATOR
Intervention: Thermal balloon ablation
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 81
Study: 18486508

Group type: EXPERIMENTAL
Intervention: Pacifier and glucose
Number of subjects: 98

Group type: COMPARATOR
Intervention: Water and pacifier
Number of subjects: 98

Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 98

Group type: COMPARATOR
Intervention: Water
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Crying-time
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Parents' cortisol and VAS
Number of subjects: 98
Study: 17497441

Group type: EXPERIMENTAL
Intervention: 80 microg intradermal (ID) vaccination
Number of subjects: 33

Group type: COMPARATOR
Intervention: 160 microg intramuscular (IM) vaccination
Number of subjects: 33
Study: 15093574

Group type: EXPERIMENTAL
Intervention: Radiotherapy + Tamoxifen for 2 years
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Radiotherapy + No Tamoxifen
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: No Radiotherapy + Tamoxifen for 2 years
Number of subjects: 347

Group type: COMPARATOR
Intervention: No Radiotherapy + No Tamoxifen
Number of subjects: 347
Study: 11210072

Group type: EXPERIMENTAL
Intervention: Flap debridement surgery (FDS) in smokers
Number of subjects: 57

Group type: COMPARATOR
Intervention: Flap debridement surgery (FDS) in non-smokers
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Deep sites (PD > or = 7 mm) in smokers
Number of subjects: 57

Group type: COMPARATOR
Intervention: Deep sites (PD > or = 7 mm) in non-smokers
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Deep sites in smokers
Number of subjects: 57

Group type: COMPARATOR
Intervention: Deep sites in non-smokers
Number of subjects: 57
Study: 9392460

Group type: EXPERIMENTAL
Intervention: 3-DCTB
Number of subjects: 13

Group type: COMPARATOR
Intervention: FOB
Number of subjects: 13
Study: 7709991

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms twice a day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Salmeterol 100 micrograms nightly
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 3593906

Group type: EXPERIMENTAL
Intervention: Ciramadol (30 mg) administered in a fasting state
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ciramadol (30 mg) administered in a postprandial state
Number of subjects: 11
Study: 31543460

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including training teachers, increasing opportunities for physical activity, reducing screen time, and health education
Number of subjects: 1085

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 1085
Study: 29334874

Group type: EXPERIMENTAL
Intervention: Telemedicine‐Enhanced Antidepressant Management intervention delivered in VA community‐based outpatient clinics (CBOCs)
Number of subjects: 759

Group type: COMPARATOR
Intervention: Outreach Using Telemedicine for Rural Enhanced Access in Community Health intervention delivered in FQHCs
Number of subjects: 759
Study: 27091875

Group type: EXPERIMENTAL
Intervention: Elotuzumab plus bortezomib/dexamethasone (EBd)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Bortezomib/dexamethasone (Bd)
Number of subjects: 152
Study: 26175538

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 4016

Group type: COMPARATOR
Intervention: Metoprolol succinate
Number of subjects: 4016

Group type: COMPARATOR
Intervention: Metoprolol therapy
Number of subjects: 4016
Study: 23921199

Group type: EXPERIMENTAL
Intervention: Nasal high-flow oxygen therapy (NHF) at 45 litre min(‐1)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Nasal high-flow oxygen therapy (NHF)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 340
Study: 21914365

Group type: EXPERIMENTAL
Intervention: salmeterol/fluticasone (50 µg/500 µg)
Number of subjects: 63

Group type: COMPARATOR
Intervention: salbutamol/ipratropium bromide (120 µg/21 µg)
Number of subjects: 63
Study: 18344725

Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole (starting dose 5 mg/d, mean end-point dose of 11.0 mg/d)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole
Number of subjects: 381
Study: 16636534

Group type: EXPERIMENTAL
Intervention: PaCO(2) target between 55 and 65 mm Hg (minimal ventilation)
Number of subjects: 65

Group type: COMPARATOR
Intervention: PaCO(2) target between 35 and 45 mm Hg (routine ventilation)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Minimal ventilation
Number of subjects: 65
Study: 15387805

Group type: EXPERIMENTAL
Intervention: Nordic hamstrings (NH) training
Number of subjects: 21

Group type: COMPARATOR
Intervention: Hamstring curl (HC) training
Number of subjects: 21
Study: 11739305

Group type: COMPARATOR
Intervention: Muscarinic receptor density measurement using PET with (11)C‐MQNB
Number of subjects: 21

Group type: COMPARATOR
Intervention: Heart rate (HR) response to intravenous infusion of isoproterenol (5 minutes after 2 mg of atropine, 5, 10, and 15 ng/kg per minute during 5 minutes per step)
Number of subjects: 21

Group type: COMPARATOR
Intervention: DeltaHR after atropine
Number of subjects: 21
Study: 9433621

Group type: EXPERIMENTAL
Intervention: Association test with selected markers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Segregation analysis with regressive models
Number of subjects: 0
Study: 8390240

Group type: EXPERIMENTAL
Intervention: Low dose (25 mg) of naltrexone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High dose (100 mg) of naltrexone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Naltrexone (both doses)
Number of subjects: 30
Study: 3080221

Group type: EXPERIMENTAL
Intervention: FUDR 0.3 mg/kg/day for 2 weeks, mitomycin C 15 mg/m2 over 1 hour every 8 weeks, BCNU 150 mg/m2 over 1 hour every 8 weeks via hepatic artery
Number of subjects: 36

Group type: COMPARATOR
Intervention: Single-agent FUDR (planned for future randomized trial)
Number of subjects: 36
Study: 29104132

Group type: EXPERIMENTAL
Intervention: Adalimumab in combination with azathioprine
Number of subjects: 176

Group type: COMPARATOR
Intervention: Adalimumab monotherapy
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Adalimumab trough levels
Number of subjects: 176
Study: 26916299

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 353
Study: 24710856

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) maintenance treatment
Number of subjects: 16
Study: 22353950

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 20456838

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) treatment (Jiangya Capsule)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Integrative treatment (Jiangya Capsule plus nimodipine)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Western medicine (WM) group (nimodipine plus Jiangya Capsule simulation)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Integrative treatment
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 270
Study: 17157857

Group type: EXPERIMENTAL
Intervention: 100 mg DINAC
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 500 mg DINAC
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: DINAC (both doses)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: DINAC (in vitro)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 16636704

Group type: EXPERIMENTAL
Intervention: Cochrane Highly Sensitive Search Strategy (HSSS) for RCTs
Number of subjects: 1347

Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trial (Publication Type)
Number of subjects: 1347

Group type: EXPERIMENTAL
Intervention: Additional search terms
Number of subjects: 1347
Study: 14982314

Group type: EXPERIMENTAL
Intervention: Exercise intervention (moderate intensity exercise 3-5 times per week for 20-30 min each time)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Increased cardiovascular fitness (on-treatment analysis)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 102
Study: 11789243

Group type: EXPERIMENTAL
Intervention: Lixin Pill (LXP)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: LXP plus small dosage of digoxin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ordinary dosage of digoxin
Number of subjects: 90
Study: 9053053

Group type: EXPERIMENTAL
Intervention: Deltamethrin impregnated mosquito nets
Number of subjects: 20000
Study: 1734794

Group type: EXPERIMENTAL
Intervention: Calcium chloride (5 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epinephrine (30 ng.kg‐1.min‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (for epinephrine group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Calcium chloride followed by epinephrine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epinephrine alone
Number of subjects: 40
Study: 6377845

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Health Education
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Behaviour Modification
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 168
Study: 31232097

Group type: EXPERIMENTAL
Intervention: Chan-Chuang qigong group (standard care plus a 10-day mind-body interactive exercise program)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (standard care only)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Covariates (neurologic deficit, muscle strength, low frequency to high frequency ratio, anxiety)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Heart rate, heart rate variability, fatigue, depression
Number of subjects: 68
Study: 30407966

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 37)
Number of subjects: 73
Study: 27050028

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (O3FAs), n = 65, twice daily for 6 months
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo (olive oil), n = 65, twice daily for 6 months
Number of subjects: 130
Study: 24841975

Group type: EXPERIMENTAL
Intervention: Elacytarabine
Number of subjects: 381

Group type: COMPARATOR
Intervention: Investigator's choice of one of seven commonly used AML salvage regimens (including high-dose cytarabine, multiagent chemotherapy, hypomethylating agents, hydroxyurea, and supportive care)
Number of subjects: 381
Study: 22749258

Group type: EXPERIMENTAL
Intervention: Early initiation of fingolimod (0.5 mg/d) for 2 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed initiation of fingolimod after 1 year of IM interferon beta-1a (IFN-β1a)
Number of subjects: 0
Study: 20547017

Group type: COMPARATOR
Intervention: HT-group (Estradiol 2 mg + NETA 1 mg)
Number of subjects: 167

Group type: COMPARATOR
Intervention: HT+C-group (Estradiol 2 mg + NETA 1 mg + 800 mg clodronate)
Number of subjects: 167

Group type: COMPARATOR
Intervention: C-group (clodronate only)
Number of subjects: 167

Group type: COMPARATOR
Intervention: HT-group
Number of subjects: 167

Group type: COMPARATOR
Intervention: HT+C-group
Number of subjects: 167

Group type: COMPARATOR
Intervention: C-group
Number of subjects: 167
Study: 17878466

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICS and long-acting beta-agonist combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: ICS
Number of subjects: 0
Study: 15531566

Group type: EXPERIMENTAL
Intervention: Asymmetric double logistic curve‐fitting procedure for circadian analysis
Number of subjects: 302
Study: 12197998

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg ascorbate/d)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU RRR-alpha-tocopheryl acetate/d)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Vitamins C + E
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Vitamin C + E
Number of subjects: 184
Study: 10194485

Group type: EXPERIMENTAL
Intervention: High-pressure, rapid-inflation pneumatic compression
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard, low-pressure, slow-inflation compression
Number of subjects: 33
Study: 7772440

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 1 ml injected into the lumen of the vas deferens
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 0.9% saline 1 ml injected into the lumen of the vas deferens
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 70
Study: 2137711

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 3000
Study: 6270295

Group type: EXPERIMENTAL
Intervention: 1500 mg of cannabidiol (CBD)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Both CBD and placebo
Number of subjects: 4
Study: 31301919

Group type: EXPERIMENTAL
Intervention: Tdap vaccine 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tdap vaccine 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTaP-primed adolescents
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTwP-primed adolescents (prior study)
Number of subjects: 0
Study: 27566108

Group type: EXPERIMENTAL
Intervention: Sleep health-care education program
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (training in subjects other than sleep)
Number of subjects: 210
Study: 27501593

Group type: EXPERIMENTAL
Intervention: Cycling programming of a sacral neuromodulator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous programming of a sacral neuromodulator
Number of subjects: 0
Study: 24417235

Group type: EXPERIMENTAL
Intervention: Brief intervention comprising brief advice including training in craving control using simple yogic breathing exercises (BA-YBA)
Number of subjects: 992

Group type: COMPARATOR
Intervention: Very brief advice (VBA)
Number of subjects: 992
Study: 22006379

Group type: EXPERIMENTAL
Intervention: High-dose ambroxol (990 mg/day) for 5 consecutive days after operation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no ambroxol treatment)
Number of subjects: 61
Study: 19713235

Group type: EXPERIMENTAL
Intervention: 10 g psyllium
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: 10 g bran
Number of subjects: 275

Group type: COMPARATOR
Intervention: 10 g placebo (rice flour)
Number of subjects: 275
Study: 17311305

Group type: EXPERIMENTAL
Intervention: BCG (81 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: BCG (27 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: BCG (27 mg) + IFN-alpha
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: BCG (81 mg) or BCG (27 mg) + IFN-alpha
Number of subjects: 80
Study: 15804000

Group type: COMPARATOR
Intervention: Therapeutic trials with a control group
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Therapeutic trials without a control group
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Randomised trials
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Therapeutic trials published
Number of subjects: 13
Study: 12086724

Group type: EXPERIMENTAL
Intervention: Formulation H
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Formulations F, G, H and I
Number of subjects: 9
Study: 9788081

Group type: EXPERIMENTAL
Intervention: Attention to visual motion
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Activity in the prefrontal cortex
Number of subjects: 1
Study: 7814830

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2698903

Group type: EXPERIMENTAL
Intervention: 5682 SE (2 tablets per day for 2 months)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Diosmin (900 mg per day for 2 months)
Number of subjects: 90
Study: 1190094

Group type: EXPERIMENTAL
Intervention: Information condition subjects administered the SHSS A in standardized manner
Number of subjects: 0

Group type: COMPARATOR
Intervention: No information subjects administered the SHSS A with usual rapport section omitted
Number of subjects: 0
Study: 29608231

Group type: COMPARATOR
Intervention: Home-based HIV testing and counselling (HB-HTC) accepted by participants (controls)
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Home-based HIV testing and counselling (HB-HTC) declined by participants (cases)
Number of subjects: 642
Study: 28460763

Group type: EXPERIMENTAL
Intervention: XIENCE V everolimus eluting stent
Number of subjects: 400
Study: 25933060

Group type: EXPERIMENTAL
Intervention: Dynamic stretching protocol
Number of subjects: 465

Group type: COMPARATOR
Intervention: Dynamic + static (D+S) stretching protocol
Number of subjects: 465
Study: 24416723

Group type: EXPERIMENTAL
Intervention: Standard therapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Sequential treatment
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 110

Group type: COMPARATOR
Intervention: Females
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Participants aged 40-77 years
Number of subjects: 110

Group type: COMPARATOR
Intervention: Participants aged 17-39 years
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Overall adherence
Number of subjects: 110
Study: 21036024

Group type: EXPERIMENTAL
Intervention: Supervised exercise sessions (8 sessions) combined with self-management education (8 sessions) over a 1-month period
Number of subjects: 38
Study: 18468273

Group type: EXPERIMENTAL
Intervention: Occivator intervention (20 minutes of stretches and exercises, two times a week for eight weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29